Biomarin Pharmaceutical (BMRN) Net Cash Flow (QoQ) (2009 - 2026)
Biomarin Pharmaceutical (BMRN) Net Cash Flow (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Biomarin Pharmaceutical | 11.33 Bn | 9.11 Bn | 571.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,815.14% |
| Dec 31, 2025 | 69.75% |
| Sep 30, 2025 | -78.85% |
| Jun 30, 2025 | 56.53% |
| Mar 31, 2025 | -59.46% |
| Dec 31, 2024 | 190.16% |
| Sep 30, 2024 | -232.43% |
| Jun 30, 2024 | 2,305.75% |
| Mar 31, 2024 | 62.24% |
| Dec 31, 2023 | -129.91% |
| Sep 30, 2023 | -20.17% |
| Jun 30, 2023 | 177.10% |
| Mar 31, 2023 | -290.46% |
| Dec 31, 2022 | -126.01% |
| Sep 30, 2022 | 866.03% |
| Jun 30, 2022 | -13.61% |
| Mar 31, 2022 | 157.20% |
| Dec 31, 2021 | -25.30% |
| Sep 30, 2021 | 10.20% |
| Jun 30, 2021 | -244.46% |